Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia
- 1 January 2003
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 19 (5) , 433-434
- https://doi.org/10.1185/030079903125002072
Abstract
(2003). Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia. Current Medical Research and Opinion: Vol. 19, No. 5, pp. 433-434. doi: 10.1185/030079903125002072Keywords
This publication has 9 references indexed in Scilit:
- Pure red-cell aplasia due to anti-erythropoietin antibodiesNephrology Dialysis Transplantation, 2003
- Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like ParticlesThe Journal of Immunology, 2002
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsPublished by Elsevier ,2002
- Pure Red-Cell Aplasia and Recombinant ErythropoietinNew England Journal of Medicine, 2002
- The Danger Model: A Renewed Sense of SelfScience, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Maintenance and loss of self-tolerance in B cellsSpringer Seminars in Immunopathology, 2001
- Peptide and Major Histocompatibility Complex–Specific Breaking of Humoral Tolerance to Native Insulin With the B9-23 Peptide in Diabetes-Prone and Normal MiceDiabetes, 2001
- Anergy and not Clonal Ignorance Determines the Fate of B Cells that Recognize a Physiological AutoantigenThe Journal of Immunology, 2001